Abstract
Introduction: Despite guideline recommendations to use low molecular weight heparin (LMWH) for the treatment of cancer associated thrombosis (CAT), the use of direct oral anticoagulatns (DOACs) is gaining more popularity given the ease of administration, lower cost, and emerging data. Here we report patient outcomes from our experience in treating CAT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
